Leipzig – Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), Europe’s leading cell bank, is laying the groundwork for accelerated growth in its core business with an extensive restructuring of its Management Board and accelerating development in its new business areas of cell-based drugs / viral vectors production (CDMO) and cell therapies (CAR-T therapies).

Effective March 22, 2022, Mr. Jakub Baran was appointed to the Management Board of Vita 34 AG. He is one of the founders and the CEO of the Polish company PBKM, which was acquired last year, and was therefore instrumental in setting up what was once the leading European stem cell bank. He takes over the position of CEO from Dr. Wolfgang Knirsch, who is leaving the Management Board and the company by mutual agreement. “Dr. Wolfgang Knirsch has shaped the success of Vita 34 to a large extent and led the company to new size and efficiency. For this achievement we would like to express our respect and at the same time our thanks,” emphasizes Dr. Alexander Granderath, Chairman of the Supervisory Board of Vita 34 AG. “With Jakub Baran as the new CEO, we herald a new era in the company’s growth story. On the cash flow-strong foundation of cell banking, we will quickly establish ourselves in the future markets of cell production and cell therapies with our expertise, which we have gained over the years, and we will continue to grow at an accelerated rate.”

Furthermore, the Management Board of Vita 34 AG will be expanded to include the newly created position of Chief Commercial Officer (CCO), with which a special focus will be placed on the development of the sales and marketing strategy of the newly created product areas as well as strategic business development. Also effective March 22, 2022, Mr. Tomasz Baran was appointed to the company’s Management Board for the position of CCO. He has also been a member of the board of the Polish PBKM since 2010 and in his function has developed extensive sales and marketing strategies for addressing new and existing customers of the company. “Vita 34 is currently entering new markets that are just emerging but are already growing rapidly,” explains the Chairman of the Supervisory Board, Dr. Alexander Granderath. “It therefore makes more than strategic sense to place a clear emphasis on customer acquisition and business development on the Management Board. Tomasz Baran brings with him exactly the experience from his board work for PBKM, which Vita 34 now needs in order to benefit optimally from the enormous momentum in the industry”.

• www.biocity-campus.com

Source: DGAP press release of March 18.03.2022th, XNUMX